
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
RAHWAY, N.J.--(BUSINESS WIRE)--May 16, 2025--
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing research for patients with this disease.
Merck will present pooled data from participants who have completed the PULSAR, SPECTRA, or STELLAR studies and have continued in the ongoing open-label extension study, SOTERIA, evaluating the long-term safety, tolerability and efficacy of WINREVAIR™ (sotatercept-csrk) when added to background therapy for the treatment of PAH. These results represent the largest analysis of WINREVAIR to date.
'The results from this pooled analysis add to the growing body of evidence for WINREVAIR,' said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. 'We remain confident in the long-term potential for WINREVAIR for patients with PAH and look forward to sharing findings as we continue to evaluate WINREVAIR.'
Merck will also present an overall survival analysis for WINREVAIR leveraging data from the pivotal Phase 3 study, STELLAR, and interim data from participants who have continued in the ongoing open-label SOTERIA study, as well as additional outcomes research on the burden and impact of PAH in various patient populations.
Details on Merck abstracts at ATS:
About WINREVAIR ™ (sotatercept-csrk) for injection, for subcutaneous use, 45 mg, 60 mg
WINREVAIR is FDA-approved for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. WINREVAIR is the first activin signaling inhibitor therapy approved to treat PAH. WINREVAIR improves the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation. In preclinical models, WINREVAIR induced cellular changes that were associated with thinner vessel walls, partial reversal of right ventricular remodeling, and improved hemodynamics.
WINREVAIR is the subject of a licensing agreement with Bristol Myers Squibb.
Selected Safety Information for WINREVAIR in the U.S.
WINREVAIR may increase hemoglobin (Hgb). Severe erythrocytosis may increase the risk of thromboembolic events or hyperviscosity syndrome. Monitor Hgb before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter, to determine if dose adjustments are required.
WINREVAIR may decrease platelet count. Severe thrombocytopenia may increase the risk of bleeding. Thrombocytopenia occurred more frequently in patients also receiving prostacyclin infusion. Do not initiate treatment if platelet count is <50,000/mm3. Monitor platelets before each dose for the first 5 doses, or longer if values are unstable, and periodically thereafter to determine whether dose adjustments are required.
In clinical studies, serious bleeding (e.g., gastrointestinal, intracranial hemorrhage) was reported in 4% of patients taking WINREVAIR and 1% of patients taking placebo. Patients with serious bleeding were more likely to be on prostacyclin background therapy and/or antithrombotic agents, or have low platelet counts. Advise patients about signs and symptoms of blood loss. Do not administer WINREVAIR if the patient is experiencing serious bleeding.
WINREVAIR may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with WINREVAIR and for at least 4 months after the final dose. Pregnancy testing is recommended for females of reproductive potential before starting WINREVAIR treatment.
Based on findings in animals, WINREVAIR may impair female and male fertility. Advise patients on the potential effects on fertility.
The most common adverse reactions occurring in the phase 3 clinical trial (≥10% for WINREVAIR and at least 5% more than placebo) were headache (24.5% vs 17.5%), epistaxis (22.1% vs 1.9%), rash (20.2% vs 8.1%), telangiectasia (16.6% vs 4.4%), diarrhea (15.3% vs 10.0%), dizziness (14.7% vs 6.2%), and erythema (13.5% vs 3.1%).
Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with WINREVAIR, and for 4 months after the final dose.
About PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( www.sec.gov ).
Please see Prescribing Information for WINREVAIR (sotatercept-csrk) athttp://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_pi.pdf, Patient Information for WINREVAIR athttp://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ppi.pdf, and Instructions for Use for WINREVAIR (1-vial kit, 2-vial kit) athttps://www.merck.com/product/usa/pi_circulars/w/winrevair/winrevair_ifu_1-vial_2-vial_kits.pdf.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515033520/en/
CONTACT: Media Contacts:
Julie Cunningham
(617) 519-6264
Courtney Ronaldo
(908) 442-5695
Investor Contacts:
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: SCIENCE CARDIOLOGY DATA ANALYTICS RESEARCH GENERAL HEALTH HEALTH PROFESSIONAL SERVICES CLINICAL TRIALS
SOURCE: Merck & Co., Inc.
Copyright Business Wire 2025.
PUB: 05/16/2025 06:45 AM/DISC: 05/16/2025 06:46 AM
http://www.businesswire.com/news/home/20250515033520/en
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Forbes
31 minutes ago
- Forbes
Another Deadly Cancer That's Potentially Been Tamed By Globalization
'In my 30 years of oncology, we haven't talked about curing myeloma.' Those are the words of University of North Carolina professor of cancer policy, Norman Sharpless, as reported in the New York Times. For those who don't know, multiple myeloma is a blood cancer that's long been known as incurable. Which raises a question: what would readers do if they received a multiple myeloma diagnosis? It's no reach to say that most of us would ask the doctor relaying the horrible news if there's any hope, any cure, or any possible cure anywhere. This would particularly be true with myeloma since the traditional path to death within a year of diagnosis is described by the Times as 'extremely painful.' Enter Legend Biotech, a Somerset, NJ biotechnology company. The Times reports that the immunotherapy developed there loomed as a 'last-ditch' option five years ago for close to 100 myeloma patients. The encouraging, beautiful news is that a third emerged from what was traditionally a death sentence alive and cancer free. To say that what's happening at Legend Biotech is an exciting development insults understatement. Finally, after all this time there's progress. And the progress exists as optimism that we're on the doorstep of many more remarkable leaps. Which requires another pause. Though Legend is based in Somerset, NJ, its origins are Chinese. It raises a question: would readers facing death refuse the treatments developed by Legend, or some other pharmaceutical corporation operating in China? One assumes the question answers itself. On matters of life and death, there's a natural tendency among humans to do whatever it takes to survive, particularly if they have children. It's just a comment that when death stares us in the face, no pause is required. We're wired to search far and wide for whatever will keep us upright. The main thing is that while Legend is now New Jersey-based, it still has operations in China. Good. The more that the world is economically integrated, the better off we all are. In other words, it's not a 'national security' threat when great leaps of the AI, financial, or pharmaceutical variety are hatched somewhere not the United States. Figure that if trading lanes are open, it's as though the world's greatest products, services and cures are all being created right next door. And when market goods are crossing borders without regard to country origin, war of the shooting and bombing kind becomes frightfully expensive. Looked at in tax terms, Legend's global footprint is hopefully a reminder to U.S. tax writers that when it comes to innovative developments meant to cure some of the worst diseases, it's extraordinarily mistaken to tax 'Made in America' more favorably than 'Made Around the World.' The more that U.S. pharmaceutical companies avail themselves of global talent, the much better that American drugs will be. And the more that tax policy is neutral as applied to U.S. corporations, the more easily they'll be able to acquire the best of the best globally. The simple, and ultimately life-saving truth is that productivity is an effect of cooperation across as many hands, machines, and machines that think as possible. Drugs aren't unique in this regard. The more specialized cooperation in the development of moon-shot style cures, the quicker the arrival at the cure. Sharpless went on to tell the Times that 'This is the first time we are really talking seriously about cures in one of the worst malignancies imaginable.' The brilliant fruits of tessellated talents at opposite sides of the world. It's just something to remember. Cliched though it may sound, there's no limit to progress when specialized genius is combined. Let's not allow tax writers to erect barriers to this collaboration solely because genius occasionally has a foreign address.


WebMD
36 minutes ago
- WebMD
Navigating Skincare: Keloids, Climate, and Consistency
As a child, the dermatologist was the doctor I visited most frequently. Between dark spots on my face, severely chapped lips, and dry skin during the winter, I was always being prescribed a new ointment or remedy to try. Today, the first two issues have been resolved thanks to healthier eating habits and finding the right skin care and lip products for me. However, I still deal with dry skin not only in the winter but throughout most of the year. I've noticed that my keloid scars, along with the surrounding areas, are particularly prone to dry skin. For those unfamiliar with keloids, they're a growth of extra scar tissue that happens where the skin has healed after an injury or surgical procedure. I've been dealing with them since I was in middle school, having developed a large one on the back of my earlobe following my ear piercing. My breast cancer treatment and surgeries introduced several more keloids into my life, including at the site of my chemo port, in the radiated area of my breast, and the largest one – a long scar across my back from one of my breast reconstruction surgeries. While they're not painful, they're often dry, itchy, and hard to reach in certain spots (like the scar on my back, which can be tricky to moisturize properly because of its location). I recently moved from Atlanta to Chicago, which has caused me to rethink my winter skin care routine, especially when it comes to my keloid-prone skin. The cold, dry air makes my scars even itchier and more dehydrated, so I've had to adjust my approach. I've found that layering an oil-based body lotion with a body oil helps my skin lock in moisture longer. Additionally, applying Vaseline to my keloids every morning and night has provided extra relief. My need for a tailored skin care routine isn't just about adapting to the colder months. It's a reminder of how I've had to advocate for my skin's unique needs throughout my health journey – from childhood to my breast cancer treatment. Many aspects of health care don't always consider the needs of people with melanin-rich skin, something I've learned time and time again. One example of this happened before starting radiation, when I was informed that the radiated area would turn darker, like a tan. However, what I experienced was nothing like a cute summer tan – my skin turned completely black and became very tender and painful. I realized early on that the standard skin care recommendations wouldn't work for my skin's needs, requiring me to look for alternatives. Taking proper care of my skin is a constant journey, especially when navigating different climates and changing seasons. I usually shop based on reviews, which has quickly taught me that what works for one person might not work for another, and that's OK. The key is to listen to your body, stay consistent, and adjust your routine to support your skin's unique needs. Whether it's layering oils during the winter or finding products that soothe and hydrate, prioritizing what works best for you is key – your skin will thank you for it.


Bloomberg
37 minutes ago
- Bloomberg
Uncertainty May Lead to 'Pothole' for Stocks: Seema Shah
"This is a tough environment for investors," Seema Shah, Principal Asset Management chief global strategist, says. Speaking on "Bloomberg Open Interest," Shah also says the Federal Reserve won't cut rates until at least the fourth quarter. (Source: Bloomberg)